Ultima Genomics
Focus: Ultima Genomics develops high-throughput, low-cost DNA sequencing platforms targeting oncology, neurology, and ophthalmology applications. The company is a publicly-traded biotech focused on enabling genomic discovery through accessible sequencing technology.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$600M
Open Jobs
17+4 this month
Stable — net +4 jobs in 30d
9 added, 5 removed. Backfill posture.
Should You Work at Ultima Genomics?
AI assessmentA platform-stage bet best suited for technologists and commercialization professionals willing to tolerate financial opacity for a stake in a disruptive sequencing technology.
Why Work Here
- Join a public-stage company with a focused platform technology rather than a crowded pipeline, offering unique exposure to instrumentation and commercialization
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ultima Genomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.